Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05673603 · ClinicalTrials.gov registry record · Phase 1
A Study of Brensocatib Following a Single Oral Administration in Participants With or Without Renal Impairment
A Phase 1 study, sponsored by Insmed Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT05673603 is a Phase 1 study that has completed, run by Insmed Incorporated. The registered enrollment target is 28 participants.
The verdict
NCT05673603, a Phase 1 study, has completed, sponsored by Insmed Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The primary purpose of the study is to determine the pharmacokinetics (PK) following a single oral dose administration of brensocatib, safety, and tolerability of brensocatib when administered to participants with impaired renal function and in healthy participants.
Interventions
- DRUG Brensocatib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2021-07-20 |
| Est. Completion | 2023-02-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05673603
The ClinicalTrials.gov registry entry for NCT05673603 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Insmed Incorporated, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Brensocatib is the first listed.
NCT05673603 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05673603 about?
NCT05673603 is a clinical study titled "A Study of Brensocatib Following a Single Oral Administration in Participants With or Without Renal Impairment". The primary purpose of the study is to determine the pharmacokinetics (PK) following a single oral dose administration of brensocatib, safety, and tolerability of brensocatib when administered to participants with impaired renal function and in healthy participants.
What is the current status of trial NCT05673603?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2021-07-20. Estimated completion is 2023-02-14.
What interventions are being tested in trial NCT05673603?
The interventions under investigation include: Brensocatib (DRUG).
Who is sponsoring clinical trial NCT05673603?
This trial is sponsored by Insmed Incorporated, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.